Invitation to presentation of Xbrane Biopharma’s interim report January-September 2019 on November 15, 2019

Corporate Information

English

News

Presentation

Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on November 15th, 2019, at 10.00 a.m. CET. Xbrane will publish the company’s interim report for the period January-September 2019, on Friday November 15th, 2019, at 8.00 a.m. CET.

Martin Åmark, CEO, and Susanna Helgesen, CFO, will present Xbrane and comment on the interim report for the period January-September 2019, followed by a Q&A session. The presentation will be in English. To attend, please dial-in at one of the numbers below:

Standard international: +44 (0) 2071 928 000
UK (Local): +44 (0) 844  571 88 92
UK (Toll free): 08  003  767 922
Sweden (Local): +46 (0) 850  692 180
Sweden (Toll free): 020  012 55 81
US (Local): +1  631  510 74 95
US (Toll free): +1  866  966 13 96

Confirmation Code: 73 79 585

Web link:
https://edge.media-server.com/mmc/p/qbduqx4h

About Us

Xbrane is a commercial phase Swedish biopharmaceutical company that develop and produces biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars. Xbrane’s headquarter is located in Solna outside of Stockholm and the company’s in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq Stockholm since September 2019 with the ticker XBRANE. For more information please visit www.xbrane.com.